[1] National Health Commission of the People's Republic of China. Diagnosis and treatment plan for COVID-19(trial version 8 revision)[J]. Chinese Journal of Clinical Infectious Diseases(中华临床感染病杂志), 2021, 14(2): 81-88. [2] Shiraki K, Daikoku T. Favipiravir an anti-influenza drug against life-threatening RNA virus infections[J/OL]. Pharmacol Ther, (2020-02-22)[2021-04-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102570/. [3] Furuta Y, Komeno T, Nakamura T.Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase[J]. Proc Jpn Acad Ser B Phys Biol Sci, 2017, 93(7): 449-463. [4] Wang XK, Sun N, Chen ZH.Progress in researches for favipiravir in anti-vital treatments[J]. Chinese Journal of New Drugs(中国新药杂志), 2019, 28(15): 1824-1827. [5] Wang M, Cao R, Zhang L, et al.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro[J]. Cell Re, 2020, 30(3): 269-271. [6] Kocayiğit H, Özmen Süner K, Tomak Y, et al.Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically ill patients with COVID-19[J]. J Clin Pharm Ther, 2021, 46(2): 454-459. [7] Cai Q, Yang M, Liu D, et al.Experimental treatment with favipiravir for COVID-19: an open-label control study[J]. Engineering (Beijing), 2020, 6(10): 1192-1198. [8] Fujii S, Ibe Y, Ishigo T, et al.Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients[J]. J Infect Chemother, 2021, 27(7): 1051-1057. [9] Yamada Koichi. Anti-influenza drug avigan tablet meets primary endpoint in phaseⅢclinical trial in Japan for COVID-19 patients[N/OL]. Fujifilm, (2020-09-23)[2021-04-01]. https://www.fujifilm.com/jp/en/news/hq/5451. [10] Ivashchenko AA, Dmitriev KA, Vostokova NV, et al.Avifavir for treatment of patients with moderate coronavirus disease 2019 (COVID-19): interim results of a phase ii/iii multicenter randomized clinical trial[J]. Clin Infect Dis, 2021, 73(3): 531-534. [11] Fu D, Cao R, Zhao L, et al.Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series[J]. Crit Care, 2020, 24(1): 578. [12] Chen PJ, Chao CM, Lai CC.Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients[J]. J Infect, 2021, 82(5): 186-230. [13] Ghasemnejad-Berenji M, Pashapour S.Favipiravir and COVID-19: a simplified summary[J]. Drug Res (Stuttg), 2021, 71(3): 166-170. [14] Zhao H, Zhang C, Zhu Q, et al. Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: a multicenter, open-label, randomized trial [J/OL]. Int Immunopharmacol, (2021-04-21)[2021-04-22]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8059985/. [15] Doi Y, Hibino M, Hase R, et al.A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19[J]. Antimicrob Agents Chemother, 2020, 64(12): e01897-20. [16] Udwadia ZF, Singh P, Barkate H, et al.Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial[J]. Int J Infect Dis, 2021, 103: 62-71. [17] Khamis F, Al Naabi H, Al Lawati A, et al.Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia [J/OL]. Int J Infect Dis, 2021, 102: 538-543. [18] Solaymani-Dodaran M, Ghanei M, Bagheri M, et al. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia[J/OL]. Int Immunopharmacol, (2021-03-11)[2021-04-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7951885/. [19] Chen PJ, Chao CM, Lai CC.Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients[J]. J Infect, 2021, 82(5): 186-230. [20] Huang W, Berube J, McNamara M, et al. Lymphocyte subset counts in COVID-19 patients: a meta-analysis[J]. Cytometry A, 2020, 97(8): 772-776. [21] Cui SP, Zhao Z, Ge ZR, et al.Analysis of early warning indexes and immune mechanism of re-positive among coronvirus disease 2019 patients[J]. International Journal of Virology, 2021, 28(1): 1-5. [22] He J, Tao H, Yan Y, et al.Molecular mechanism of evolution and human infection with SARS-CoV-2[J]. Viruses, 2020, 12(4): 428. [23] Ison MG, Scheetz MH. Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19[J/OL]. EBioMedicine, (2021-01-06)[2021-04-01].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785424/. |